Want to see LPCN full AI Analyst Report?
Top Page
Lipocine
(NASDAQ:LPCN)
Select Model
Select Model
Rating:47Neutral
Price Target:
$2.00
▼(-6.98% Downside)
Action:Reiterated
Date:09/10/26
The score is driven primarily by weak financial performance (declining revenue, sizable losses, and ongoing cash burn), partially cushioned by a debt-free balance sheet. Technicals are neutral with only mild near-term support and a weak longer-term trend. Valuation is constrained by negative earnings and no dividend, while corporate events provide only a modest positive signal.
Positive Factors
Debt-free balance sheet
A debt-free balance sheet reduces exposure to interest expense, refinancing pressure, and lender constraints while the company advances its pipeline. This provides greater financial flexibility than a similarly loss-making business carrying substantial borrowing, although equity is still being consumed by ongoing losses.
Negative Factors
Declining revenue
Shrinking revenue indicates that Lipocine currently has limited and weakening commercial or other recurring revenue support. Without a sustained improvement from TLANDO, partnerships, or pipeline monetization, declining top-line performance can constrain investment in development and make operating results less predictable.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
A debt-free balance sheet reduces exposure to interest expense, refinancing pressure, and lender constraints while the company advances its pipeline. This provides greater financial flexibility than a similarly loss-making business carrying substantial borrowing, although equity is still being consumed by ongoing losses.
Read all positive factors
Lipocine (LPCN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$19.46M
Dividend YieldN/A
Average Volume (3M)38.71K
Price to Earnings (P/E)―
Beta (1Y)0.45
Revenue Growth-62.70%
EPS Growth-121.27%
CountryUS
Employees14
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.87
Shares Outstanding8,244,253
10 Day Avg. Volume32,787
30 Day Avg. Volume38,712
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.02
Price to Sales (P/S)22.14
P/FCF Ratio-4.48
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$6.00Price Target Upside179.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.9
Revenue Forecast (FY)$776.40K
Lipocine Business Overview & Revenue Model
Company Description
Lipocine Inc. is a biopharmaceutical firm currently in the clinical development phase, concentrating its efforts on creating medicinal products to address a range of neuroendocrine and metabolic conditions. A core aspect of the company's research ...
How the Company Makes Money
Lipocine’s business model has historically been typical of a clinical-stage biopharmaceutical developer: it seeks to generate value by advancing proprietary drug candidates through research and clinical development and then monetizing them through...
Lipocine Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.57M | 1.98M | 11.20M | -2.85M | 500.00K | 16.14M |
| Gross Profit | 1.54M | -6.61M | 11.20M | -13.03M | -8.06M | 8.48M |
| EBITDA | -11.79M | -9.57M | 50.14K | -16.32M | -10.72M | -430.53K |
| Net Income | -11.85M | -9.63M | 8.35K | -16.35M | -10.76M | -634.40K |
Balance Sheet | ||||||
| Total Assets | 23.84M | 17.01M | 22.51M | 23.00M | 37.54M | 52.48M |
| Cash, Cash Equivalents and Short-Term Investments | 23.27M | 14.93M | 21.63M | 22.04M | 32.53M | 44.62M |
| Total Debt | 0.00 | 449.59K | 0.00 | 0.00 | 0.00 | 2.31M |
| Total Liabilities | 2.07M | 2.53M | 1.51M | 2.63M | 1.91M | 6.91M |
| Stockholders Equity | 21.77M | 14.48M | 21.00M | 20.37M | 35.63M | 45.57M |
Cash Flow | ||||||
| Free Cash Flow | -11.19M | -9.76M | -1.31M | -11.88M | -12.10M | -4.42M |
| Operating Cash Flow | -11.19M | -9.76M | -1.22M | -11.87M | -11.97M | -4.41M |
| Investing Cash Flow | -6.15M | 5.89M | 2.45M | 13.08M | 14.29M | -43.78M |
| Financing Cash Flow | 16.27M | 2.87M | 209.34K | 404.57K | -2.13M | 26.92M |
Lipocine Technical Analysis
Negative
2.15
Price Trends
2.22
Positive
2.26
Negative
4.49
Negative
Market Momentum
0.05
Negative
51.85
Neutral
60.99
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LPCN, the sentiment is Negative. The current price of 2.15 is below the 20-day moving average (MA) of 2.18, below the 50-day MA of 2.22, and below the 200-day MA of 4.49, indicating a neutral trend. The MACD of 0.05 indicates Negative momentum. The RSI at 51.85 is Neutral, neither overbought nor oversold. The STOCH value of 60.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LPCN.
Lipocine Risk Analysis
Lipocine disclosed 61 risk factors in its most recent earnings report. Lipocine reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Lipocine Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $16.80M | -1.45 | -569.36% | ― | ― | 63.72% | |
47 Neutral | $19.46M | -1.20 | -64.75% | ― | -62.70% | -121.27% | |
46 Neutral | $79.11M | -3.87 | -47.92% | ― | -75.00% | 74.04% | |
44 Neutral | $5.09M | -1.35 | -109.26% | ― | -100.00% | 49.19% |
* Healthcare Sector Average
LPCN
Lipocine
2.25
-0.75
-25.00%
IBIO
Ibio
1.26
0.38
42.86%
PULM
Pulmatrix
1.48
-3.52
-70.40%
BCDA
BioCardia
1.10
-1.02
-48.11%
ASBP
Aspire Biopharma Holdings
8.61
-524.79
-98.39%
Lipocine Corporate Events
Business Operations and Strategy
Lipocine to Present at H.C. Wainwright Investment Conference
Positive
Sep 10, 2026
Lipocine Inc., a specialty biopharmaceutical company listed on NASDAQ, develops novel orally delivered therapeutics targeting large, unmet-need markets such as depressive disorders, epilepsy, essential tremor, obesity, liver cirrhosis, and preterm...
Business Operations and StrategyExecutive/Board Changes
Lipocine Appoints Industry Veteran Grissinger to Board
Positive
Aug 3, 2026
On August 3, 2026, Lipocine Inc., a biopharmaceutical firm specializing in oral drug delivery, announced the appointment of industry veteran Michael J. Grissinger to its Board of Directors, effective the same day. Grissinger brings more than two d...
Business Operations and StrategyProduct-Related Announcements
Lipocine Advances LPCN 1154 for Postpartum Depression
Positive
Jun 12, 2026
On June 12, 2026, Lipocine hosted a virtual key opinion leader event to highlight the unmet medical needs in postpartum depression and to present the clinical profile of its investigational therapy LPCN 1154. By convening experts to discuss this c...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.